Search Results - "BRAUN, Michael S"

Predictive Biomarkers of Chemotherapy Efficacy in Colorectal Cancer: Results From the UK MRC FOCUS Trial by Braun, Michael S, Richman, Susan D, Quirke, Philip, Daly, Catherine, Adlard, Julian W, Elliott, Faye, Barrett, Jennifer H, Selby, Peter, Meade, Angela M, Stephens, Richard J, Parmar, Mahesh K B, Seymour, Matthew T

“…Candidate predictive biomarkers for irinotecan and oxaliplatin were assessed in 1,628 patients in Fluorouracil, Oxaliplatin, CPT-11: Use and Sequencing…”
Get full text

Association of Molecular Markers With Toxicity Outcomes in a Randomized Trial of Chemotherapy for Advanced Colorectal Cancer: The FOCUS Trial by BRAUN, Michael S, RICHMAN, Susan D, THOMPSON, Lindsay, DALY, Catherine L, MEADE, Angela M, ADLARD, Julian W, ALLAN, James M, PARMAR, Mahesh K. B, QUIRKE, Philip, SEYMOUR, Matthew T

“…Predicting efficacy and toxicity could potentially allow individualization of cancer therapy. We investigated putative pharmacogenetic markers of chemotherapy…”
Get full text

Balancing the efficacy and toxicity of chemotherapy in colorectal cancer by Braun, Michael S., Seymour, Matthew T.

“…As the therapeutic options for the treatment of colorectal cancer have expanded over the past 20 years, so has the complexity of decision making. The goals of…”
Get full text

Measuring variation in the quality of systemic anti-cancer therapy delivery across hospitals: A national population-based evaluation by Boyle, Jemma M., van der Meulen, Jan, Kuryba, Angela, Cowling, Thomas E., Booth, Christopher, Fearnhead, Nicola S., Braun, Michael S., Walker, Kate, Aggarwal, Ajay

“…To date, there has been little systematic assessment of the quality of care associated with systemic anti-cancer therapy (SACT) delivery across national…”
Get full text

Impact of patient choice and hospital competition on patient outcomes after rectal cancer surgery: A national population‐based study by Han, Lu, Boyle, Jemma M., Walker, Kate, Kuryba, Angela, Braun, Michael S., Fearnhead, Nicola, Jayne, David, Sullivan, Richard, Meulen, Jan, Aggarwal, Ajay

“…Background The objective of the current national cohort study was to analyze the correlation between choice and competition on outcomes after cancer surgery in…”
Get full text

Survival outcomes associated with completion of adjuvant oxaliplatin‐based chemotherapy for stage III colon cancer: A national population‐based study by Boyle, Jemma M., Kuryba, Angela, Cowling, Thomas E., Meulen, Jan, Fearnhead, Nicola S., Walker, Kate, Braun, Michael S., Aggarwal, Ajay

“…The impact of cycle completion rates of oxaliplatin‐based adjuvant chemotherapy for stage III colon cancer in real‐world practice is unknown. We assessed its…”
Get full text

What is the impact of hospital and surgeon volumes on outcomes in rectal cancer surgery? by Boyle, Jemma M, van der Meulen, Jan, Kuryba, Angela, Cowling, Thomas E, Braun, Michael S, Aggarwal, Ajay, Walker, Kate, Fearnhead, Nicola S

“…Evidence for a positive volume-outcome relationship for rectal cancer surgery is unclear. This study aims to evaluate the volume-outcome relationship for…”
Get full text

Validity of chemotherapy information derived from routinely collected healthcare data: A national cohort study of colon cancer patients by Boyle, Jemma M., Kuryba, Angela, Braun, Michael S., Aggarwal, Ajay, van der Meulen, Jan, Cowling, Thomas E., Walker, Kate

“…•Routinely collected chemotherapy data was validated using hospital administrative data.•Adjuvant chemotherapy use, regimen, and cycle number were compared…”
Get full text

Inequalities in the recovery of colorectal cancer services during the COVID‐19 pandemic: a national population‐based study by Boyle, Jemma M., Kuryba, Angela, Blake, Helen A., Meulen, Jan, Fearnhead, Nicola S., Braun, Michael S., Walker, Kate

“…Aim Evidence is lacking on whether there were inequalities in the recovery of colorectal cancer (CRC) services within the English National Health Service (NHS)…”
Get full text

Development and validation of a coding framework to identify severe acute toxicity from systemic anti-cancer therapy using hospital administrative data by Boyle, Jemma M., Cowling, Thomas E., Kuryba, Angela, Fearnhead, Nicola S., van der Meulen, Jan, Braun, Michael S., Walker, Kate, Aggarwal, Ajay

“…The capture of toxicities from systemic anti-cancer therapy (SACT) in real-world data will complement results from clinical trials. The aim of this study was…”
Get full text

Outcomes of colorectal cancer resection in patients with inflammatory bowel disease: a national population‐based analysis in England and Wales by Kuryba, Angela J., Vallance, Abigail E., Boyle, Jemma M., Braun, Michael S., Blake, Helen A., Meulen, Jan, Fearnhead, Nicola S., Walker, Kate

“…Aim The aim was to compare early postoperative outcomes and 2‐year cancer‐specific mortality following colorectal cancer (CRC) resection in patients with and…”
Get full text

Phase I and Pharmacokinetic Study of Intravenous Irinotecan Plus Oral Ciclosporin in Patients With Fluorouracil-Refractory Metastatic Colon Cancer by CHESTER, John D, JOEL, Simon P, CHEESEMAN, Susan L, HALL, Geoffrey D, BRAUN, Michael S, PERRY, Jackie, DAVIS, Theresa, BUTTON, Christopher J, SEYMOUR, Matthew T

“…Purpose: To assess the safety and toxicity profile of escalating doses of intravenous irinotecan, in combination with a fixed dose of oral ciclosporin (Cs) and…”
Get full text

Molecular markers of chemotherapeutic response and toxicity in colorectal cancer by Braun, Michael S, Quirke, Philip, Seymour, Matthew T

“…Outcomes in colorectal cancer have improved over the last 15 years; this is in part due to the optimization of 5-fluorouracil schedules and the introduction of…”
Get full text

Are we delivering high-quality medical oncology care? A national comparison of severe acute toxicity from systemic anti-cancer therapy by Boyle, Jemma M, Meulen, Jan van der, Kuryba, Angela, Cowling, Thomas E, Booth, Christopher, Fearnhead, Nicola S, Braun, Michael S, Walker, Kate, Aggarwal, Ajay

“…In the precision medicine era the complexity of systemic anti-cancer therapy (SACT) delivery and their associated toxicities have also increased. However,…”
Get full text

Review: Balancing the efficacy and toxicity of chemotherapy in colorectal cancer by Braun, Michael S, Seymour, Matthew T

“…As the therapeutic options for the treatment of colorectal cancer have expanded over the past 20 years, so has the complexity of decision making. The goals of…”
Get full text

Molecular Markers of Chemotherapy Toxicity in Colorectal Cancer by Braun, Michael S., Seymour, Matthew T.

“…Personalized medicine appears to be the inevitable consequence of improvements in our understanding of the mechanisms of action of chemotherapeutic agents, as…”
Get full text

Molecular Markers of Chemotherapy Response in Colorectal Cancer by Braun, Michael S., Seymour, Matthew T.

“…Biomarkers with predictive value and, to a lesser extent, prognostic value hold the potential to revolutionize the clinical practice of oncology. During the…”
Get full text

Predictive Biomarkers of Chemotherapy Efficacy in Coorectal Cancer : SResults From the UK MRC FOCUS Trial by BRAUN, Michael S, RICHMAN, Susan D, PARMAR, Mahesh K. B, SEYMOUR, Matthew T, QUIRKE, Philip, DALY, Catherine, ADLARD, Julian W, ELLIOTT, Faye, BARRETT, Jennifer H, SELBY, Peter, MEADE, Angela M, STEPHENS, Richard J

Get full text

Phase I and pharmacokinetic study of intravenous irinotecan plus oral ciclosporin in patients with fuorouracil-refractory metastatic colon cancer by Chester, John D, Joel, Simon P, Cheeseman, Susan L, Hall, Geoffrey D, Braun, Michael S, Perry, Jackie, Davis, Theresa, Button, Christopher J, Seymour, Matthew T

“…To assess the safety and toxicity profile of escalating doses of intravenous irinotecan, in combination with a fixed dose of oral ciclosporin (Cs) and to…”
Get full text